The 2024 conference has 28 late-breakers plus plenty of basic and population science. More than anything, it’s a celebration.

Completed dosing of 115 participants in a bioavailability and bioequivalence (BA/BE) clinical trial in Australia for IHL-42X, an investigational treatment for obstructive sleep apnea in July 2024.

Inc. ( an integrated pharmaceutical company dedicated to the worldwide development and commercialization of impactful ...

Databricks, the Data and AI company, today unveiled a new Economist Impact report, "Unlocking Enterprise AI: Opportunities ...

Companies such as Roche and Novartis have demonstrated that European companies can nevertheless compete in the field of AI.

The FDA issued its first stamp of approval for a cell or gene therapy back in 2017 to Novartis' Kymriah. | The gene therapy ...

Researchers from organizations with new access to Truveta Data include American Heart Association, Bayer, Edwards Lifesciences, Eli Lilly and Co., Gates Ventures, GORE, Impulse Dynamics, Indiana ...

The Edgecombe County Board of Commissioners heard some good news last week at its monthly meeting. For the first time in ...

Following their declassification, the former protected witnesses are now facing the political figures they had named as ...

Meanwhile, Switzerland’s relative regulatory independence, via its own health authority Swissmedic, could provide some ...

Midtown-based drug discovery company Schrodinger has entered a deal to advance multiple projects with pharmaceutical giant ...

Aldeyra received an FDA CRL for reproxalap, necessitating an additional study for DED approval. Read why I continue to rate ...